Management of Refractory Symptoms in Elderly Patients with Vascular Dementia and a History of Tardive Dyskinesia

Introduction to Treatment Options

• The American Geriatrics Society recommends avoiding combinations that increase metabolism or add risks of excessive sedation in elderly patients with vascular dementia and a history of tardive dyskinesia 1

Medication Considerations

• The use of risperidone at doses above 2 mg/day significantly increases the risk of extrapyramidal symptoms in elderly patients with dementia, which is concerning given the patient's history 2
• Olanzapina should be avoided in this patient due to the increased risk of metabolic effects and weight gain in the elderly, as well as a higher risk of excessive sedation when combined with other sedative medications 3

Monitoring and Implementation

• It is essential to monitor for excessive sedation, cognitive impairment, and the risk of falls, given the sedative profile of quetiapine, and to assess extrapyramidal symptoms weekly for the first 4 weeks using a standardized scale 2, 3
• The Mayo Clinic recommends reevaluating the need for continuation after 3-6 months of symptomatic control, attempting to reduce to the lowest effective dose 4

Critical Warnings

• All antipsychotics increase mortality in elderly patients with dementia (FDA black box warning), and there is an increased risk of cerebrovascular events (stroke, TIA) in this population 2
• The American Geriatrics Society suggests discussing risks and benefits with family members or caregivers before initiating treatment 2

Treatment Duration

• For agitated dementia, attempt gradual reduction after 3-6 months to determine the lowest effective maintenance dose, and discontinuation should be gradual over more than 1 month to avoid withdrawal symptoms 4
• If there is no response after 4 weeks at an adequate dose, consider gradual reduction and discontinuation 2